PANASONIC-CORPORATION
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005399/en/
Panasonic sought the agreement with Ms. Osaka after observing that her values and perspectives on society deeply resonate with its own management philosophy, primarily with regard to the following three points:
First, Ms. Osaka takes social issues seriously, looking beyond tennis to share her views on what a better society would look like in her own words. The founder of Panasonic, Konosuke Matsushita, held the notion that a stable state of happiness comes only when both mental stability and material prosperity are secured. Based on this idea, the company endeavors to create an ideal society where all of us can enjoy lives that are both mentally fulfilling and affluent in the material sense.
Second, Ms. Osaka’s intense and powerful playing is a source of energy and courage for people all over the world. Panasonic has passed down the founder’s view that the mission of an enterprise is to achieve a prosperous society and to make people happy, and continues to work toward fulfilling a strong aspiration not only to provide products needed by society, but also to make customers who use them feel happy and uplifted.
And third, Ms. Osaka continues to grow and evolve as her magnificent track record being one of the world’s top athletes is the result of her tireless efforts to refine each and every move in the course of her daily training and matches. Panasonic also continues to grow and evolve in a range of fields, aiming to elevate its expertise for the benefit of customers and society and achieve constant evolution.
At this time, Panasonic and Ms. Osaka have concluded a brand ambassador agreement to join hands in an endeavor to create an ideal society for each and every person, positioning “A Champion. For Progress.” as our shared commitment.
Ms. Osaka has shown she has the courage to take action in the face of adversity. Panasonic will provide her with heartfelt support.
Reference:
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/
(Short version)
Naomi Osaka
Profile:
Date of birth: October 16, 1997
Place of birth: Osaka City, Osaka
Height: 180 cm
Naomi Osaka was born to a Japanese mother and a Haitian-American father, who moved her to New York in the United States when she was three years old. She is now based in Florida.
Major achievements:
- 2013: Started her professional career in tennis
- July 2014: Qualified for the first time for the Women’s Tennis Association (WTA) Tour Championships in Stanford
- January 2016: Advanced to the third round at the Australian Open, her Grand Slam debut
- 2016: Also advanced to the third round at the French Open (Roland-Garros) and the US Open Tennis Championships, where she recorded a serve speed of 201.1 km/h
- September 2016: Toray Pan Pacific Open Tennis Tournament runner-up
- October 2016: Named “Newcomer of the Year” at the 2016 WTA Awards, becoming the first Japanese player to win the award
- March 2018: BNP Paribas Open champion
- August 2018: US Open Tennis Championships champion
- January 2019: Australian Open champion
- September 2019: China Open tennis champion
- September 2019: Toray Pan Pacific Open Tennis Tournament champion
- August 2020: US Open Tennis Championships champion
- February 2021: Australian Open champion
Current WTA Ranking: 2nd
Qualified to play at the Olympic Games Tokyo 2020 (Women’s tennis, singles)
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 522 subsidiaries and 69 associated companies worldwide and reported consolidated net sales of 6,698.8 billion yen for the year ended March 31, 2021. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global
Source: https://news.panasonic.com/global/press/data/2021/06/en210624-3/en210624-3.html
Related Links
- Panasonic’s management philosophy
https://www.panasonic.com/global/corporate/management/philosophy.html#section_02
- Why Panasonic Appointed Naomi Osaka
https://channel.panasonic.com/contents/33222/
- "A CHAMPION. FOR PROGRESS." - Naomi Osaka, a brand ambassador of Panasonic
https://channel.panasonic.com/contents/33217/
https://channel.panasonic.com/contents/33219/
(Short version)
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005399/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom